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ABSTRACT 
Purpose 
To derive a mapping algorithm to predict SF-6D utility scores from the non-preference-based 
LupusQoL and test the performance of the developed algorithm on a separate independent validation 
data set. 
Method 
LupusQoL and SF-6D data were collected from 320 patients with systemic lupus erythematosus 
(SLE) attending routine rheumatology outpatient appointments at seven centres in the UK. Ordinary 
least squares (OLS) regression was used to estimate models of increasing complexity in order to 
predict individuals’ SF-6D utility scores from their responses to the LupusQoL questionnaire. Model 
performance was judged on predictive ability through the size and pattern of prediction errors 
generated. The performance of the selected model was externally validated on an independent data set 
containing 113 female SLE patients who had again completed both the LupusQoL and SF-36 
questionnaires. 
Results 
Four of the eight LupusQoL domains (physical health, pain, emotional health, and fatigue) were 
selected as dependent variables in the final model. Overall model fit was good, with R
2
 0.7219, MAE 
0.0557, and RMSE 0.0706 when applied to the estimation data set, and R
2
 0.7431, MAE 0.0528, and 
RMSE 0.0663 when applied to the validation sample. 
Conclusion 
This study provides a method by which health state utility values can be estimated from patient 
responses to the non-preference-based LupusQoL, generalisable beyond the data set upon which it 
was estimated. Despite concerns over the use of OLS to develop mapping algorithms, we find this 
method to be suitable in this case due to the normality of the SF-6D data. 
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INTRODUCTION 
Economic evaluations are increasingly needed to guide decisions on how to best allocate scarce health 
care resources. In order to compare across different health conditions and interventions, the results of 
such evaluations must be expressed in a common metric. International advisory bodies such as The 
National Institute for Health and Care Excellence (NICE) in England and Wales[1], The Academy of 
Managed Care Pharmacy (AMCP) in the US[2] and The Canadian Agency for Drugs and 
Technologies in Health (CADTH)[3] have specified cost-utility analysis (CUA) as the preferred form 
of economic evaluation, with quality-adjusted life years (QALYs) therefore being used as the 
common metric of health benefit. The QALY is a measure of health which combines length and 
health-related quality of life (HRQoL) into a single number. The quality dimension of the QALY 
represents the utility associated with a health state, and can be estimated using a preference-based 
measure of health. These preference-based measures attribute a pre-scored health state classification 
system which has been valued using preferences elicited from samples of the general public, referred 
to as utility, to responses to patient-reported outcome measures (PROMs). Despite this need for utility 
data, many trials fail to include a preference-based measure of health. Non-preference based disease-
specific measures are often favoured as these instruments are thought to be more relevant to the 
patient populations being examined, and more responsive to changes in health resulting from 
treatment[4]. 
 
One solution increasingly being employed by analysts faced with a lack of available utility data is 
empirical mapping[5, 6]. Mapping involves estimating a statistical relationship between a non-
preference based measure and a preference-based measure of HRQoL, using a dataset in which both 
measures have been administered to the same patients. The resulting model or algorithm can then be 
used to predict health state utility values for patients that have only completed the non-preference 
based instrument. Various model specifications can be used, ranging from a simple linear function 
where the utility score of the preference-based measure is regressed onto the total score of the non-
preference based measure, to complex ‘response mapping’ models.  Response mapping models 
predict how patients would have responded to the preference-based questionnaire using separate 
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models to predict the response for each dimension of a PROM[7]. Brazier and colleagues provide a 
useful review of published mapping studies for those unfamiliar with the approach[5]. 
 
The LupusQoL[8] is one such disease-specific non-preference based measure, developed in order to 
specifically assess the impact of systemic lupus erythematosus (SLE) and its treatment upon the 
HRQoL of people with the condition SLE[8]. SLE is a relapsing/remitting autoimmune multi-system 
disease of unknown aetiology[9]. The nature of the disease is such that it can affect different organs 
and systems in different patients, and can evolve over time. SLE has various manifestations including 
joint and muscle ache, rashes, extreme fatigue, hair loss, ulcers, anxiety and depression[10]. Around 
90% of  patients are women[10], with incidence highest in those of child-bearing age, and in non-
Caucasian populations[11]. There is no cure for the condition, which has been shown to impose a 
substantial burden in term of HRQoL[10, 12], and treatment is therefore aimed at reducing disease 
activity and frequency of relapse. Few medications are currently licensed for the treatment of SLE, 
and the commonly used immune-suppressants can be associated with significant adverse events. 
However, the new age of biological therapies has seen a number of novel therapies being developed to 
treat the condition, showing promising results in terms of clinical-effectiveness[13]. The impact of 
these new treatments upon HRQoL will need to be evaluated, along with their cost-effectiveness, if 
they are to be widely implemented into clinical practice. 
 
The objective of this article was to derive a mapping algorithm to predict SF-6D utility scores from 
the non-preference based LupusQoL, and test the performance of the developed algorithm on a 
separate independent validation data set. 
 
METHODS 
Instruments 
The LupusQoL[8] 
The LupusQoL provides a profile of scores across 8 domains of HRQoL: physical health (8 items), 
pain (3 items), planning (3 items), intimate relationships (2 items), burden to others (3 items), 
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emotional health (6 items), body image (5 items), and fatigue (4 items) (Appendix A1). These items 
were derived using qualitative interviews with clinicians and patients to identify areas most relevant 
for SLE populations, and so provide a rich source of information. Each item is scored on a 5 point 
Likert scale and mean raw domain scores are transformed onto a scale of 0-100, with higher numbers 
representing better HRQoL. Transformed domain scores can be calculated providing at least 50% of 
item answers are completed. 
 
The instrument has acceptable ceiling and minimal floor effects, and demonstrates good internal 
reliability (Cronbach’s alpha 0.88 to 0.96), test-retest reliability (r 0.72 to 0.93), concurrent validity 
with the comparable domains of the SF-36 (r 0.71 to 0.79), and discriminant validity for different 
levels of disease activity as measures by the British Isles Lupus Assessment Group (BILAG) index 
[8]. The sensitivity to change has been shown to be comparable to that detected by the SF-36[14]. The 
LupusQoL has been translated into 77 languages for use in 52 countries, and been used successfully in 
a number of clinical trials[15]. However, in its current form the LupusQoL is not amenable for use in 
CUA as it is not preference-based[4, 16]. 
 
The SF-6D[17–19] 
The SF-6D is a generic preference-based measure of HRQoL derived from the SF-36[20, 21] or SF-
12[22]. It covers 6 domains of HRQoL: physical functioning, role limitations, social functioning, 
pain, mental health, and vitality. Preference weights can be applied to the SF-6D health state 
classification to produce a single index utility score ranging from 0.296-1 when derived from the SF-
36, where 1 represents a state of full health. The SF-6D has been found to be an appropriate measure 
of HRQoL for people with SLE [23], demonstrating acceptable psychometric properties [24] and 
displaying construct and criterion validity [25]. 
Both instruments are self-reported questionnaires which ask respondents to consider their HRQoL 
over the last 4 weeks. 
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Data 
Estimation data set 
Data collected from 320 patients during the LupusQoL development and validation study was used to 
estimate the mapping algorithm[8]. Patients were approached whilst attending routine rheumatology 
outpatient appointments at seven centres in the UK, and so characterise a representative sample of the 
general SLE population. All patients met four or more of the revised American College of 
Rheumatology (ACR) criteria for SLE[26, 27], were at least 18 years old, literate in English and 
without major unstable psychiatric disease.  
Validation data set 
 
A separate independent data set from a study investigating carotid atherosclerosis in SLE was used to 
test the validity of the developed mapping function[25, 28]. Data were collected from 113 female 
patients over the age of 18 who again met four or more of the revised American College of 
Rheumatology (ACR) criteria for SLE[26, 27]. Patients were recruited from outpatient clinics in the 
North West of England. As the original study was designed to collect DNA for genetic studies, 
recruitment was restricted to white British women. 
Patients in both data sets completed both the LupusQoL and the SF-36 questionnaires at the same 
follow-up assessments. 
 
Statistical analysis 
The correlation between paired observations was examined using Pearson’s product-moment 
correlation coefficients, as the performance of any mapping function is dependent upon the strength of 
the underlying relationship between the two measures used. Whilst LupusQoL scores are normally 
reported as a profile of 8 domain scores, it was agreed with the developers that for the purpose of this 
exercise domain scores could be summed to create a total score ranging from a possible 0 – 800 (KM, 
L-ST JA). A higher total score represents better HRQoL. 
 
7 
 
Although ordinary least squares (OLS) regression is the most widely used method for developing 
mapping algorithms[5], there has been debate in the recent literature over its use to analyse HRQoL 
data[6, 29]. These issues, however, are mainly directed at the suitability of OLS for predicting EQ-5D 
utility scores due its bi- or often tri-modal distribution[29] and the well documented ceiling effect of 
the instrument[30, 31], which typically results in a concentration of observations at 1. A number of 
studies have found OLS to be appropriate when mapping to the SF-6D, often finding this method to 
demonstrate superior performance to alternatives such as Tobit, CLAD, two-part models and response 
mapping methods in this context [32–34].  The distribution of the SF-6D scores in both the estimation 
and validation data sets were therefore tested for normality in order to assess the appropriateness of 
OLS to model this particular relationship. 
 
Various model specifications were estimated in an attempt to find the best fit, upon which the final 
mapping algorithm was then based. The SF-6D utility score was used as the dependent variable 
throughout, and models estimated first using LupusQoL total score and then domain scores as 
explanatory variables. Squared and first degree interaction terms, plus age and gender patient 
characteristics were then added to investigate whether these improved model fit. OLS regression was 
used and a backward stepwise elimination procedure employed, retaining variables with a P-value < 
0.05 and excluding those with P > 0.10. Given the size of the data set and the large number of possible 
responses to the LupusQoL (five possible responses on each of the 34 items), the data was not rich 
enough to accurately allow estimation of models using LupusQoL item scores as dependent variables 
or response mapping.  
 
A number of different criteria were examined in order to assess model performance within the 
estimation data set. As the purpose of the function is to predict SF-6D utility scores from LupusQoL 
data, the size and pattern of the prediction errors is the primary concern[5, 6], therefore the mean 
absolute error (MAE) and root mean squared error (RMSE) were calculated at the individual patient 
level to assess the size of the prediction errors. Smaller MAE and RMSE values indicate greater 
predictive accuracy. As there are no current guidelines indicating what level of prediction errors are 
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acceptable, results are compared to those reported for other published mapping functions. In addition, 
observed SF-6D values were plotted against those predicted and the residuals of these predictions in 
order to examine the pattern of errors across the scale of the SF-6D. The range of predicted values 
from the developed algorithm are reported and compared to the range of observed SF-6D scores to 
assess the extent to which the model was affected by the commonly encountered problems of poor fit 
at the extremes if the distribution, systematic error patterns and compression of range[5]. 
Furthermore, the proportion of absolute prediction errors below 0.05 and 0.1 were calculated. 
 
The same criteria were used to assess the model when applied to the independent validation data set, 
where we are again concerned with the size and pattern of the prediction errors. External validation 
assesses the performance of the mapping algorithm at its primary purpose; to predict SF-6D utility 
scores using LupusQoL responses in an unrelated data set. Additionally, the accuracy with which the 
developed model was able to predict the mean SF-6D score for the validation data set was examined. 
The ability to predict mean scores is important, as practical applications of mapping generally involve 
estimating utility values at this aggregate level rather than predicting individual health states[5, 6]. 
Furthermore, assessment of predicted mean scores is only relevant when applying the model to the 
independent validation data set, as OLS estimates the unknown parameters of a model so as to 
minimise the sum of the squared errors, and so the mean value of the predicted scores will equal that 
of the observed in the data upon which the model was estimated. Although written primarily to guide 
exercises mapping to the EQ-5D, throughout we follow the latest recommendations for good practice 
where applicable[6]. All analysis was undertaken using Stata version 13. 
 
RESULTS 
Descriptive statistics 
Demographic and clinical characteristics of the patients in both the estimation and validation data sets 
are shown in Table 1. Patients in the estimation data set cover the full range of possible SF-6D scores, 
with a mean score of 0.615 (SD 0.130). A broad range of LupusQoL scores are observed, ranging 
from 26 – 800, with a mean of 509 (SD 182). The full range of possible scores on each LupusQoL 
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item are covered, apart from the physical health domain where observed scores range from 3 – 100. 
The correlation coefficient of r = 0.824 between total LupusQoL and SF-6D scores indicates a strong 
correlation between the two measures[35]. The strength of the correlation between the LupusQoL 
domain scores when considered individually and the SF-6D vary from 0.580 for the body image 
domain to 0.805 for the physical health domain. Mean SF-6D scores for patients in the validation 
sample (0.638 (SD 0.138)) were similar to those in the estimation sample, although the range of 
observed SF-6D scores was smaller (0.327 – 1). The range of total LupusQoL scores observed in the 
validation sample was also reduced, ranging from 106 – 800 with a mean of 494 (SD 194). The full 
range of possible scores are observed for six of the eight LupusQoL items, with scores on the 
emotional health domain ranging from 25 – 100 and from 8 – 100 for body image. A strong 
correlation exists between LupusQoL and SF-6D (correlation coefficient r = 0.847). The magnitudes 
of the correlations between the LupusQoL domain scores and the SF-6D are marginally larger for all 
domains in the validation sample, varying from 0.622 for the intimate relationships domain to 0.816 
for the physical health domain. 
 
Figure 1 shows the distribution of SF-6D scores in the estimation and validation samples. We fail to 
reject the null hypothesis of normality at either the 5% or 10% significance level in either data set 
(p=0.130 estimation sample, p=0.198 validation sample), indicating that OLS is appropriate in this 
situation. 
 
Selected model and performance 
The addition of squared and first degree interaction terms, age, and gender did not improve the 
predictive accuracy of the basic OLS model, and so these were not selected for inclusion in the final 
algorithm. 
 
The specification for the selected model is shown in Table 2, alongside the model including all of the 
LupusQoL domains for comparison. There is very little difference between these two models in terms 
of the size of the coefficients, statistical significance, explanatory power, or the size of the prediction 
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errors generated. This indicates that the items not selected for the final model contribute very little to 
predicting SF-6D utilities, and so excluding these increases the efficiency of the final model. Four of 
the eight LupusQoL domains were selected for inclusion using the stepwise procedure: physical 
health (PH), pain (P), emotional health (EH), and fatigue (F). The coefficients relating to the constant 
and LupusQoL items displayed in the table are those produced by the stepwise regression, and are 
multiplied by the score on the corresponding LupusQoL item in order to calculate the predicted SF-
6D score as follows: 
𝑆𝐹 − 6𝐷 𝑢𝑡𝑖𝑙𝑖𝑡𝑦
= 0.3040964 + 0.0014778 ∗ 𝑃𝐻 + 0.0014531 ∗ 𝑃 + 0.0011405 ∗ 𝐸𝐻
+ 0.0008953 ∗ 𝐹 
 
The small magnitude of the coefficients reflects the fact that each LupusQoL item is scored 0-100.  
The performance statistics for the selected model are shown in Table 3. Within the estimation data set 
overall model fit was good, with more than 70% of the variation in SF-6D utility scores explained by 
the four selected items of the LupusQoL. MAE is 0.0557, which is towards the lower end of the range 
of MAEs reported in a recent systematic review of published mapping functions (MAE 0.0011 to 
0.19)[5]. This MAE equates to an average prediction error in the magnitude of 8% of the total scale 
covered by the SF-6D (0.296 – 1). The RMSE was 0.0706, which is lower than that of any reported in 
the same systematic review (RMSE 0.084 to 0.2). Figure 2 plots the observed SF-6D values against 
those predicted by the model, and the prediction errors, illustrating the fit of the model with the 
estimation data set. The model predicts well for the majority of the SF-6D scale, but suffers from 
problems of under-prediction at the upper end. The under-prediction is caused by the inability of the 
model to predict utility scores larger than 0.801. The majority of errors were small in absolute 
magnitude, with 88% of predictions within 0.1 of the observed value and 52% within 0.05. 
 
Model performance in the independent validation data set was comparable, which suggests that the 
developed mapping function between the LupusQoL and the SF-6D represents a strong statistical 
relationship which is applicable outside of the estimation data set. 74% of the variation in SF-6D 
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utility scores was explained by the model. The MAE was 0.0528 and RMSE 0.0663, both marginally 
lower than in the estimation data set. Figure 3 plots the observed SF-6D values in the validation data 
set against those predicted by the model, and the prediction errors, showing similar model fit to that 
observed in the estimation data set. The model again predicts well for the majority of the SF-6D scale, 
but the problem of under-prediction at the upper end persists. The majority of errors were again small 
in absolute magnitude, with 93% of predictions within 0.1 of the observed value and 54% within 0.05. 
Finally, the model performed extremely well when predicting the mean SF-6D utility score for the 
validation sample. The observed mean was 0.624 and the predicted mean 0.617. 
 
CONCLUSIONS 
This study provides a method by which health state utility values can be estimated from patient 
responses to the non-preference based disease-specific LupusQoL measure. The developed mapping 
algorithm performs well in comparison to other published studies[5], and so provides a practical 
solution for researchers seeking to use existing datasets where the LupusQoL but no preference-based 
utility measure is collected for economic evaluation. The encouraging performance of the mapping 
function may be a product of the conceptual similarity of the LupusQol and the SF-6D measures 
compared with other mapping functions which attempt to map to preference-based HRQoL measures 
from more narrow measures of outcome, such as the Heath Assessment Questionnaire which 
measures functional disability[36]. The validation of the model using an independent data set is also a 
strength of the study, demonstrating the generalizability of the developed algorithm beyond the data 
set upon which is was estimated. 
 
Four of the eight LupusQoL dimensions were selected for inclusion in the final model: physical 
health, pain, emotional health, and fatigue. The inclusion of these domains is not surprising given the 
conceptual overlap of these dimensions with those of the SF-6D: physical functioning, role 
limitations, social functioning, pain, mental health, and vitality. Nor is it surprising that gender did not 
significantly improve the predictive accuracy of the model, given the predominance of females in the 
sample. The remaining four dimensions of the LupusQoL; planning, intimate relationships, burden to 
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others, and body image, are clearly of importance to people with SLE [8]. The omission of these 
dimensions from the final model does not dispute this, but reflects that these domains do not 
significantly impact upon utility as measured by the SF-6D. Whilst the collection of both a generic 
preference-based and a disease-specific measure of HRQoL remains the preferred method, the strong 
statistical relationship demonstrated means that researchers concerned about the burden placed upon 
patients by administering multiple measures may be able to obtain the necessary clinical information 
from just using the LupusQoL, and predict utility scores based upon these responses. However, the 
longitudinal validity of this algorithm, which has highlighted limitations in other mapping 
functions[37], has not yet been tested. Therefore, we reiterate previous recommendations to include at 
least one preference-based measure of HRQoL in all relevant clinical studies wherever possible[37–
39]. The lack of interchangeability among different preference-based measures should also be 
considered by those wishing to use the algorithm presented here, as it has been developed to predict 
utility as measured by the SF-6D, and so may produce different values to HRQoL measured by 
another preference-based measure such as the EQ-5D[40]. The impact of using different preference-
based measures on QALY estimates has been demonstrated and discussed in the field of 
rheumatology[41, 42]. 
 
Although the predictive accuracy of the mapping function is impressive, the model is unable to 
predict utility scores above 0.801. A recent study has highlighted that regression to the mean may be 
the cause of the reduction in variance and prediction range often observed in mapping studies [43]. 
However, this would affect both the upper and lower ends of the scale. As our function does not suffer 
from an inability to predict scores at the lower end of the SF-6D range, it appears more likely that the 
problem is due to a lack of observations in the estimation data set covering high SF-6D scores. This 
absence is a reflection of the large detrimental effect of SLE on HRQoL[10]. In our representative 
samples of outpatients, just 9% of the estimation and 10% of the validation sample have observed SF-
6D scores above this level. In the context of economic evaluations it is the error at group level which 
is important[44, 45], which was shown to be minimal when the model was applied to the independent 
validation data. Caution should however be aired if applying the function to a particularly mild patient 
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population, or if treatment is expected to return HRQoL to near full health. The restriction of our 
validation sample to white British women means that we were unable to test the developed model on 
an entirely representative SLE population. However, previous analysis performed on our estimation 
sample found no significant differences in LupusQoL scores by sex or ethnicity as classified as Black-
Caribbean, Asian, and White[46]. This restriction is therefore likely to have minimal implications for 
the validity of our exercise. 
 
Despite concerns over the use of OLS, we find this method of estimation to be suitable in this case 
due to the normality of the SF-6D data. Alternative methods for mapping, such as the linking (scale-
aligning)[43, 47], have been proposed to overcome the limitations of OLS, such as the inability to 
predict accurately in high and low regions of the scale due to regression to the mean. However, in our 
case we were unable to operationalise this approach as we considered some of the conditions required 
for this technique to be violated[43], most notably that there is no official overall scale for the 
LupusQoL to link to an overall SF-6D scale measuring the same construct of HRQoL.  Whilst we 
used a ‘total’ LupusQoL score for exploratory purposes in this study, this is currently neither 
validated nor recommend for clinical use. The development of an overall LupusQoL score, especially 
if combined with preference-based values of the health states described, would represent an important 
development, both for the measure itself and in allowing further refinement of its relationship with the 
SF-6D.  
 
In agreement with previous studies[5], we find a simple additive model with the utility score as the 
dependent variable and dimension scores as independent variables to be the most appropriate 
functional form, with the addition of squared terms, first degree interactions, and patient 
characteristics having little impact on model performance. Our results do, however, oppose previous 
observations that the degree of error tends to be larger when mapping from a disease-specific measure 
rather than another generic instrument[2]. The strong predictive results observed in this study are 
likely due to the nature of the disease in question. The breadth of symptoms resulting from SLE and 
its various manifestations mean that the LupusQoL domains cover a much broader range of HRQoL 
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elements than many other disease-specific measures. Mapping relies on the conceptual overlap 
between the two measures used, not only so that the generic measure is able to capture all of the 
relevant effects of the disease in question, but also to ensure that the disease-specific instrument is 
able to capture comorbidities and side effects of potential treatments. There appears to be sufficient 
overlap between the SF-6D and LupusQoL to allow the estimation of a useful mapping function. 
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Table 1 Characteristics of the estimation and validation samples 
Characteristic Estimation sample (n = 320) Validation sample (n = 113) 
Age, years, mean (SD) 44.8 (13.6) 48.6 (9.3) 
Female, % 95 100 
Disease duration, years, mean (SD) 10.5 (8.7) 12.6 (9.7) 
SF-6D index score, mean (SD), range 0.615 (0.130) 
0.296 - 1 
0.638 (0.138) 
0.327 - 1 
LupusQoL total score, mean (SD), 
range 
509 (182) 
26 - 800 
494 (194) 
106 - 800 
LupusQoL domain scores, mean (SD), 
range 
  
Physical Health 61 (27) 
3 - 100 
58 (27) 
0 - 100 
Pain  65 (27) 
0 - 100 
63 (29) 
0 - 100 
Planning 66 (30) 
0 - 100 
67 (29) 
0 - 100 
Intimate Relationships  61 (33) 
0 - 100 
59 (34) 
0 - 100 
Burden to Others 58 (28) 
0 - 100 
62 (29) 
0 - 100 
Emotional Health 73 (21) 
0 - 100 
77 (19) 
25 - 100 
Body Image 72 (26) 
0 - 100 
70 (26) 
8 - 100 
Fatigue 52 (26) 
0 - 100 
53 (28) 
0 - 100 
Pearson’s correlation coefficient 
between paired LupusQol and SF-6D 
scores, r 
0.824 
 
0.847 
 
Bivariate Pearson’s correlation 
coefficients between paired LupusQoL 
domain and SF-6D utility scores, r 
  
Physical Health  0.805 0.816 
Pain  0.789 0.811 
Planning  0.692 0.697 
Intimate Relationships 0.611 0.622 
Burden to Others  0.636 0.684 
Emotional Health  0.667 0.761 
Body Image  0.580 0.690 
Fatigue  0.737 0.747 
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Figure 1 Distribution of SF-6D scores in the estimation (upper) and validation (lower) samples 
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Table 2 Model containing all LupusQoL domains and selected model for predicting SF-6D utility scores 
from patients’ LupusQoL scores 
 Model including all LupusQoL domains Selected stepwise model 
Domain β Standard 
Error 
p value β Standard 
Error 
p value 
Physical Health (PH) 0.0014747 0.0004132 < 0.001 0.0014778 0.0003839 < 0.001 
Pain (P) 0.0014480 0.0003319 < 0.001 0.0014531 0.0003247 < 0.001 
Planning -0.0001061 0.0002853 0.710    
Intimate Relationships 0.0000107 0.0001952 0.957    
Burden to Others 0.0001495 0.0002392 0.533    
Emotional Health (EH) 0.0011993 0.0003634 0.001 0.0011405 0.0002972 <0.001 
Body Image -0.0000789 0.0002653 0.766    
Fatigue (F) 0.0008937 0.0003180 0.005 0.0008953 0.0003046   0.004 
Constant 0.3037726 0.0168842 < 0.001 0.3040964 0.0162895 < 0.001 
Adjusted R
2 
0.7136 0.7175 
RMSE 0.0711 0.0706 
 
 
 
 
Table 3 Performance of selected model in the estimation and validation data sets 
Performance Estimation data Validation data 
No. of observations 256 109 
R
2
 0.7219 0.7431 
MAE
 
0.0557 0.0528 
RMSE 0.0706 0.0663 
Predictions within ± 0.05 of observed value  52% 54% 
Predictions within ± 0.1 of observed value  88% 93% 
Range of observed values 0.296 – 1.00 0.327 – 0.938 
Range of predicted values 0.324 – 0.801 0.392 – 0.801 
Mean observed SF-6D (SD)  0.624 (0.130) 
Mean predicted SF-6D (SD)  0.617 (0.116) 
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Figure 2 Observed and predicted SF-6D values and prediction errors for the model applied to the 
estimation data set 
 
 
Figure 3 Observed and predicted SF-6D values and prediction errors for the model applied to the 
validation data set 
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APPENDIX 
Table A1. Overview of the domains and items of the LupusQoL 
LupusQol Domain Aspects of life covered by each LupusQoL item 
Physical Health 1. Help needed to do heavy physical jobs e.g. digging the garden, 
decorating, moving furniture 
 2. Help needed to do moderate physical jobs e.g. vacuuming, ironing, 
shopping, cleaning the bathroom 
 3. Help needed to do light physical jobs e.g. cooking, opening jars, 
dusting, combing my hair, attending to personal hygiene 
 4. Unable to perform everyday tasks as well as I would like to e.g. my job, 
childcare, housework 
 5. Difficulty climbing stairs 
 6. Have lost some independence and am reliant on others 
 7. Have to do things at a slower pace 
 8. Sleep pattern is disturbed 
Pain 9. Prevented from performing activities the way I would like because of 
pain 
 10. Pain experienced interferes with the quality of my sleep 
 11. Pain is so severe it limits my mobility 
Planning 12. I avoid planning to attend events in the future 
 13. Unable to organise my life efficiently due to the unpredictability of my 
Lupus 
 14. Difficult to commit to social arrangements because symptoms vary 
from day to day 
Intimate Relationships 15. Less interested in a sexual relationship due to the pain I experience 
 16. Not interested in sex 
Burden to Others 17. Concerned that my Lupus is stressful for those close to me 
 18. Concerned that I cause worry to those close to me 
 19. Feel that I am a burden to my friends and/or family 
Emotional Health 20. Resentful  
 21. So fed up nothing can cheer me up 
 22. Sad 
 23. Anxious 
 24. Worried  
 25. Lacking in self-confidence 
Body Image 26. Physical appearance interferes with my enjoyment of life 
 27. My appearance (e.g. rash, weight gain/loss) makes me avoid social 
situations 
 28. Skin rashes make me feel less attractive 
 29. Hair loss I have experienced makes me feel less attractive 
 30. Weight gain I have experienced because of my treatment makes me feel 
less attractive 
Fatigue 31. Cannot concentrate for long periods of time 
 32. Feel worn out and sluggish 
 33. Need to have early nights 
 34. Often exhausted in the morning 
Respondents are asked to read the statement for each item, and choose one of five responses which most closely 
relates to how they feel. Each statement is phrased in relation to a respondent’s Lupus, and asks them to 
consider the previous four week period. A copy of the LupusQoL questionnaire can be found in [8]. 
 
